Lexeo Therapeutics, Inc. (LXEO)
(Delayed Data from NSDQ)
$15.46 USD
-0.02 (-0.13%)
Updated May 24, 2024 04:00 PM ET
After-Market: $15.45 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
LXEO 15.46 -0.02(-0.13%)
Will LXEO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LXEO
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics reports Q1 results
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)